Overview

NeuroEM Therapeutics is a Phoenix-based medical device company committed to developing, clinically testing, and marketing Transcranial Electromagnetic Treatment (TEMT) as an effective treatment for Alzheimer’s Disease & other neurodegenerative diseases. We believe our non-invasive bioengineering technology has the potential to stop, and reverse the progressive memory impairment of Alzheimer’s Disease.

NeuroEM Therapeutics “first-in-class” MemorEM™ device was designed to be comfortably worn on the head to administer TEMT during daily in-home treatment. The electromagnetic waves emanating from multiple emitters in the MemorEM head cap disaggregate toxic protein ‘oligomers’ within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer’s Disease, we believe the MemorEM head device will directly attack the Alzheimer’s Disease process. Our pioneering TEMT technology has shown extraordinary promise against AD in all completed preclinical and clinical studies. NeuroEM’s MemorEM head device will be available through neurologists and other health professionals who diagnose memory disorders once we complete our pivotal trial and receive FDA approval.

Management / Advisors

GARY. W. ARENDASH, PH.D.

CEO and FOUNDER

Dr. Arendash was a Full Professor and Research Professor at the University of South Florida for 30 years. During the last 6 years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core. Dr. Arendash’s research expertise involves development of therapeutics against Alzheimer’s Disease. He has published over 100 peer-reviewed articles in first tier journals, including Science, Nature and the Journal of Alzheimer’s Disease – the last of which he has held the position of Senior Editor. During his academic career at USF, Dr. Arendash was awarded $5 million in research support from extramural granting agencies, including the National Institutes of Health (NIH) and the Alzheimer’s Disease and Related Disease Association (ADRDA). He was among the very first to provide evidence that Alzheimer’s Disease starts in the brain decades before it is diagnosed. Publication of Dr. Arendash’s landmark study in 2010 providing the first evidence that electromagnetic treatment provides cognitive benefit to Alzheimer’s mice resulted in worldwide interest from the news media. Dr. Arendash is the Founder of NeuroEM Therapeutics and has served as its CEO for most of the past seven years. Dr. Arendash received his Ph.D in Neuroscience/Physiology at the University of California, San Francisco (UCSF). He then did his post-doctoral research at UCLA’s Brain Research Institute prior to joining the faculty at the University of South Florida.

JON W. McGARITY

Chief Business Officer and Co-Founder

Mr. McGarity has extensive experience in senior management positions in the pharmaceutical/biotechnology/medical device industries having held executive positions at several large companies including Sandoz Pharmaceuticals(Novartis), Bristol Myers and Glaxo,Inc. He has been instrumental in the founding, management and development of a number of early stage companies as well as having raised significant equity thru IPO, Secondary and Convertible debt instruments. Jon co-founded and was Vice Chairman, President & Chief Operating Officer of Pharmaceutical Marketing Services, Inc., a publicly traded technology, data services and consulting business to the international pharmaceutical industry. He also founded and served as the President & CEO of the Arizona BioIndustry Association and has been recognized with the Arizona Bioscience Leader of the Year Award in his name.  Jon has launched over 40 products as well as completing numerous business development deals involving product acquisitions, licensing, co-marketing and promotional arrangements.  Along with Dr. Arendash and Mr. Scritsmier, he is one of the three original founders and the first CEO of NeuroEM Therapeutics, Inc.

Lyle Scritsmier

Chief Financial Officer and Co-Founder

Mr. Scritsmier has over 40 years of financial and operating management experience in the pharmaceutical services, healthcare, and medical device industries, including several companies that were introducing new technological solutions to an existing marketplace.  He has served as CFO and senior financial executive in a variety of companies ranging from start-ups to publicly traded companies.  Lyle has extensive experience in business development, mergers and acquisitions, strategic alliances, raising venture capital, revenue sharing contracts and IPO’s.    He was the senior financial executive in companies raising over $300 million of investment funding and negotiated a revenue share agreement in exchange for receiving equipment valued in excess of $25 million.  Former positions include CFO of Pharmaceutical Marketing Services Inc. a NASDAQ traded worldwide provider of sales and marketing services to the pharmaceutical industry, CFO of U.S. Administrators, the nation’s largest third party administrator, CFO and co-founder of iPhysicianNet, a company providing video enabled pharmaceutical sales promotion to 8,000 primary care physicians, CFO and Executive Vice President of MedApps Holding Company, a remote patient monitoring medical device company which was acquired by Alere Inc., a NYSE, traded company, and CFO of Prismic Pharmaceuticals, a specialty pharmaceutical company, which was acquired by FSD Pharma, a Canadian company which focuses on developing novel solutions for brain and inflammatory disorders.

Peter Moriarty

Chairman, Corporate Development Advisory Board

Mr. Moriaty has extensive experience in the pharmaceutical and healthcare industries both in the United States and internationally. He was a co-founder of Shire Pharmaceuticals, an international specialty pharmaceutical company acquired by Takeda Pharmaceuticals (TAK: NASDAQ). Peter was also the co-founder, Chairman and Chief Executive Officer of Prismic Pharmaceuticals, a specialty pharmaceutical company acquired by FSD Pharma (HUGE: NASDAQ) in 2019. Peter’s earlier career spanned management positions within Warner-Lambert/ Parke-Davis and Schering- Plough, including leadership positions overseas as well as in the United States. Additionally, he led the Sales Force Automation and Software Products Division at Walsh America, and Corporate Development at Ixsys /Applied Molecular Evolution, acquired by Eli Lilly (LLY – NYSE). Peter was subsequently the founder, Chairman and Chief Executive Officer of iPhysicianNet, Inc. and Clinical Information Network.

ROB BARANOWSKI, M.S

Advisor for Product Development

5Robert Baranowski is Founder and President of Left Coast Engineering (Escondido, CA). He leads most of the design projects for the company. With more than 25 years of electrical design experience for both military and commercial projects, Rob also has extensive hardware design experience in wireless, power, audio, controllers, location-aware and sensors. His software design and development experience involves user interfaces, drivers and applications. Rob and Left Coast Engineering have designed, tested, and produced the first generation (Gen1) MemorEM head devices utilized by NeuroEM Therapeutics in the company’s Pilot clinical trial. Rob and Left Coast Engineering are currently finalizing the development and initial production of NeuroEM’s Gen 2 MemorEM devices, which will be utilized in all of the company’s future clinical trials. He is an inventor on 20 issued patents, as well as on seven CIP and PCT applications submitted by NeuroEM within the past 1½ years. Previously, Rob was with Sony and Motorola in their cellular design and special projects groups. He holds a Masters of Electrical Engineering from Villanova University. Active in the community, Rob has founded a non-profit instructional baseball program and coaches high school baseball.

Collaborators / Partners

Memorem Device Development

  • Left Coast Engineering

    Rob Baranowski,
    Senior Engineering Project Lead

  • RF Exposure Lab

    Jay Moulton, Vice-President

  • Ocotillo Electromagnetics:

    David Wittwer, Ph.D.
    Richard Ziolkowski, Ph.D.

  • Remarkable Technologies

    Eric Knight, President

Clinical Trials

  • USF Health/Byrd Alzheimer’s Institute

    Amanda Smith MD

  • Axiom Clinical Research of Florida

    Susan Steen, M.D.
    Haitham Abulaban, MBBS, CCRC

  • Invicro/Konica Minolta

    Gary Wisniewski, Ph.D.
    Lino Becerra, M.D.

Basic Science/SBIR Research

  • MegaNano Biotech Inc.

    Chuanhai Cao, Ph.D.

  • University of South Florida

    Dr. Chuanhai Cao, Ph.D.
    Ziaopeng Li, Ph.D.
    Jing Wang, Ph.D.

Scientific Advisory Board

Huntington Potter, Ph.D.

Dr. Huntington Potter is Professor of Neurology, member of the Linda Crnic Center for Down Syndrome, and Director of the Rocky Mountain Alzheimer’s Disease Center at the University of Colorado Anschutz Medical Campus. He is devoted to studying the mechanistic relationship between Alzheimer’s Disease and Downs syndrome, recognizing that these disorders are two sides of the same coin.  Prior to joining UC Denver, Dr. Potter studied, researched and taught for 30 years at Harvard University. He received his AB Cum Laude in Physics and Chemistry and his MA and PhD in Biochemistry and Molecular Biology before spending 13 years on the faculty of the Neurobiology Department. In 1998, Dr. Potter joined the Faculty at the University of South Florida as the Eric Pfeiffer Chair for Research on Alzheimer’s Disease. He designed and directed the NIA-designated Florida Alzheimer’s Disease Research Center at USF and from 2004-2008 he was CEO of the Johnnie B. Byrd Sr. Alzheimer’s Center & Research Institute  during this time, the Institute built the largest free-standing Alzheimer’s disease research institute in the world.  Dr. Potter discovered that Alzheimer’s disease and Down syndrome, which invariably leads to Alzheimer’s by age 30-40, are mechanistically related to each other through the development of cells with abnormal numbers of chromosomes; this is the focus of his current research at UC Denver. He is author of over 100 scientific articles/books and is the holder of 15 U.S. and foreign patents.  In 2010, Dr. Potter was elected a Fellow of the American Association for the Advancement of Science and was selected one of Colorado’s Top Thinkers of 2013 by the Denver Post.  His electron micrographs of DNA are on permanent exhibit in the National American History Museum of the Smithsonian Institute in Washington D.C.

Dr. Richard Caselli

Dr. Caselli is Associate Director and Clinical Core Director of the Alzheimer’s Disease Center at Mayo Clinic in Arizona, which focuses on symptomatic patients with mild cognitive impairment and dementia.  He is also a Professor of Neurology at Mayo Clinic’s College of Medicine.  Dr. Caselli has served at Mayo’s Scottsdale campus since 1990 and is also recent Past Chairman of Mayo’s Department of Neurology.  He holds an adjunct clinical faculty appointment at the Biodesign Institute at Arizona State University, serves as an Adjunct Professor at ASU’s Department of Biomedical Informatics, and currently is a Member of the Advisory Board of the Center for Services Leadership of the W.P. Carey School of Business at ASU.  Dr. Caselli also serves on the board of directors of the Arizona Alzheimer’s Consortium.  He is certified by the American Board of Electrodiagnostic Medicine, American Board of Neurology and Psychiatry, and National Board of Medical Examiners. Dr. Caselli received both his M.D. and bachelor’s degrees from Columbia University in New York.  He served an internship and residency at Mayo Graduate School of Medicine and a fellowship in behavioral neurology and cognitive neuroscience at the University of Iowa College of Medicine.  The research program of Dr. Caselli focuses on cognitive aging and the changes that can be detected before the symptomatic onset of memory loss and related symptoms of Alzheimer’s disease.  His personal focus is on the neuropsychological and related behavioral changes in AD that can be detected.  Through a close series of collaborations, he is also involved in brain imaging (FDG-PET, PIB-PET and MRI), neuropathology, genomics, and epigenetic factors that influence Alzheimer’s disease risk and age of onset.

Ranjan Duara, M.D.

Dr. Duara is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center. He is also Associate Director of the University of Florida/Mt. Sinai Alzheimer’s Disease Research Center, and director of its clinical core based at Mount Sinai.  Through his work as co-director and clinical core leader of the Florida Alzheimer’s Disease Research Center and principal investigator of the Alzheimer’s Disease Initiative’s Florida Brain Bank, Dr. Duara has helped to enhance what is known about the biology of the disease. In May 2005, Dr Duara and his team, in collaboration with the Johnnie Byrd Alzheimer’s Institute at the University of South Florida in Tampa, received a prestigious grant from the National Institutes of Health (NIH) to become one of 31 Alzheimer’s Disease Research Centers (ADRC) in the U.S to conduct cutting-edge research on Alzheimer’s. Dr. Duara is an Associate Professor of Medicine, Neurology and Psychiatry at the University of Miami School of Medicine.  He completed neurology residencies in the United Kingdom and at Thomas Jefferson University Hospital in Philadelphia, and did a fellowship in neuroscience and neuroimaging at the National Institutes of Health. His research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 150 articles in peer-review scientific journals and has been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.